Aprotinin versus tranexamic acid during liver transplantation: Impact on blood product requirements and survival

Transplantation

Volumn 91, Issue 11, 2011, Pages 1273-1278

  Massicotte, Luc ^a   Denault, André Y ^a   Beaulieu, Danielle ^a   Thibeault, Lynda ^a   Hevesi, Zoltan ^b   Roy, André ^a  

^a CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^b UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

Antifibrinolytic; Aprotinin; Liver transplantation; Survival; Tranexamic acid; Transfusion

Indexed keywords

APROTININ; CREATININE; HEMOGLOBIN; TRANEXAMIC ACID;

ADULT; AGED; ARTICLE; BLEEDING; BLOOD TRANSFUSION; CONTROLLED STUDY; CORRELATION ANALYSIS; CREATININE BLOOD LEVEL; DRUG EFFICACY; ERYTHROCYTE TRANSFUSION; FEMALE; HEMOGLOBIN BLOOD LEVEL; HUMAN; INTRAOPERATIVE PERIOD; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MORTALITY; PHLEBOTOMY; PRIORITY JOURNAL; PROSPECTIVE STUDY; SURVIVAL;

ADULT; AGED; ANTIFIBRINOLYTIC AGENTS; APROTININ; ERYTHROCYTE TRANSFUSION; FEMALE; HUMANS; LIVER TRANSPLANTATION; LOGISTIC MODELS; MALE; MIDDLE AGED; SURVIVAL RATE; TRANEXAMIC ACID;

EID: 79958250005     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e31821ab9f8     Document Type: Article

References (46)

1. Butler P, Israel L, Nusbacher J, et al. Blood transfusion in liver transplantation. Transfusion 1985; 25: 120.
2. Porte RJ. Coagulation and fibrinolysis in liver transplantation: Current views and insights. Semin Thromb Hemost 1993; 19: 191.
3. Kang Y. Transfusion based on clinical coagulation monitoring does reduce hemorrhage during liver transplantation. Liver Transpl Surg 1997; 3: 655.
4. Steib A, Gengenwin N, Freys G, et al. Predictive factors of hyperfibrinolytic activity during liver transplantation in cirrhotic patients. Br J Anaesth 1994; 73: 645.
5. Segal H, Cottam S, Potter D, et al. Coagulation and fibrinolysis in primary biliary cirrhosis compared with other liver disease and during liver transplantation. Hepatology 1997; 25: 683.
6. Massicotte L, Lenis S, Thibeault L, et al. Effect of low central venous pressure and phlebotomy on blood product transfusion requirements during liver transplantations. Liver Transpl 2006; 12: 117.
7. Vestraete M. Clinical application of inhibitors of fibrinolysis. Drugs 1985; 29: 236.
8. Royston D. High-dose aprotinin therapy:Areview of the first five years' experience. J Cardiothorac Vasc Anesth 1992; 6: 76.
9. Westaby S. Aprotinin in perspective. Ann Thorac Surg 1993; 55: 1033.
10. Porte RJ, Molenaar IQ, Begliomini B, et al. Aprotinin and transfusion requirements in liver transplantation: A multicentre randomised double-blind study. EMSALT study group. Lancet 2000; 355: 1303.
11. Lentschener C, Roche K, Ozier Y. A review of aprotinin in liver transplantation: Can its harmful effects offset its beneficial effects? Anesth Analg 2005; 100: 1248.
12. Molenaar IQ, Warnaar N, Groen H, et al. Efficacy and safety of antifibrinolytic drugs in liver transplantation: A systematic review and metaanalysis. Am J Transpl 2007; 7: 185.
13. Neuhaus P, Bechstein WO, Lefèbre B, et al. Effect of aprotinin on intraoperative bleeding and fibrinolysis in liver transplantation. Lancet 1989; 2: 924.
14. Xia VW, Steadman RH. Antifibrinolytics in liver transplantation: Current status and controversies. Liver Transpl 2005; 11: 10.
15. Dalmau A, Sabaté A, Koo M, et al. The prophylactic use of tranexamic acid and aprotinin in live transplantation: A comparative study. Liver Transpl 2004; 10: 279.
16. Boylan JF, Klinck JR, Sandler AN, et al. Tranexamic acid reduces blood loss transfusion requirements and coagulation factor use in primary liver transplantation. Anesthesiology 1996; 85: 1043.
17. Ickx BE, Van Der Linden PJ, Melot C, et al. Comparison of the effects of aprotinin and tranexamic acid on blood loss and red blood cell transfusion requirements during the late stages of liver transplantation. Transfusion 2006; 46: 595.
18. Findlay JY, Rettke SR, Ereth MH, et al. Aprotinin reduces red blood cell transfusion in liver transplantation: A prospective, randomized, double-blind study. Liver Transpl 2001; 7: 802.
19. Mangano DT, Tudor IC, Dietzel C. Multicenter study of perioperative ischemia research group; and the ischemia research and education foundation. The risk associated with aprotinin in cardiac surgery. N Engl J Med 2006; 354: 353.
20. Fergusson DA, Hebert PC, Mazer CD, et al. A comparison of aprotinin and lysine analogues in high-risk cardiac surgery. N Engl J Med 2008; 29: 2319.
21. Molenaar IQ, Begliomini B, Grazi GL, et al. European multicenter study on the use of aprotinin in liver transplantation. The effect of aprotinin on renal function in liver transplantation. Transplantation 2001; 71: 247.
22. Warnaar N, Mallett SV, de Boer MT, et al. The impact of aprotinin on renal function after liver transplantation: An analysis of 1,043 patients. Am J Transpl 2007; 7: 2378.
23. Warnaar N, Mallett SV, Klinck JR, et al. Aprotinin and the risk of thrombotic complications after liver transplantation: A retrospective analysis of 1492 patients. Liver Transpl 2009; 15: 747.
24. Massicotte L, Sassine MP, Lenis S, et al. Transfusion predictors in liver transplant. Anesth Analg 2004; 98: 1245.
25. Massicotte L, Beaulieu D, Thibeault L. Low central venous pressure during liver transplantation. J Cardiothorac Vasc Anesth 2008; 22: 315.
26. Kufner RP. Antifibrinolytics do not reduce transfusion requirements in patients undergoing liver transplantation. Liver Transpl Surg 1997; 3: 668.
27. Kufner RP. Use of antifibrinolytics in liver transplantation. Transpl Proc 2000; 32: 636.
28. Massicotte L, Lenis S, Thibeault L, et al. Reduction of blood product transfusions during liver transplantation. Can J Anaesth 2005; 73: 545.
29. Contandriopoulos A-P, Champagne F, Potvin L, et al. Savoir préparer une recherche: la définir, la structurer, la financer. Montréal, Qc, Canada: Les presses de l'université de Montréal 1990, chap 2, p 49.
30. Steib A, Freys G, Lehmann C, et al. Intraoperative blood losses and transfusion requirements during adult liver transplantation remain difficult to predict. Can J Anesth 2001; 48: 1075.
31. McCluskey SA, Karkouti K, Wijeysundera DN, et al. Derivation of a risk index for the prediction of massive blood transfusion in liver transplantation. Liver Transpl 2006; 12: 1583.
32. Modanliou KA, Oliver DA, Grossman BJ. Liver donor's age and recipient's serum creatinine predict blood component use during liver transplantation. Transfusion 2009; 49: 2645.
33. Massicotte L, Beaulieu D, Thibeault L, et al. Coagulation defects do not predict blood product requirements during liver transplantation. Transplantation 2008; 85: 956.
34. Massicotte L, Beaulieu D, Roy JD, et al. MELD score and blood product requirements during liver transplantation: No link. Transplantation 2009; 87: 1689.
35. Massicotte L, Capitano U, Beaulieu C, et al. Independent validation of a model predicting the need for packed red blood cell transfusion at liver transplantation. Transplantation 2009; 15: 386.
36. Cacciarelly TV, Keeffe EB, Moore DH, et al. Effect of intraoperative blood transfusion on patient outcome in hepatic transplantation. Arch Surg 1999; 134: 25.
37. Ramos E, Dalmau A, Sabate A, et al. Intraoperative red blood cell transfusion in liver transplantation: Influence on patient outcome, prediction of requirements, and measures to reduce them. Liver Transpl 2003; 9: 1320.
38. Massicotte L, Sassine MP, Lenis S, et al. Survival rate changes with transfusion of blood products during liver transplantation. Can J Anesth 2005; 52: 148.
39. Hendriks HG, Van Der Meer J, de Wolf JT, et al. Intraoperative blood transfusion requirement is the main determinant of early surgical reintervention after liver transplantation. Transpl Int 2005; 17: 673.
40. Boyd SD, Stenard F, Lee DK, et al. Alloimmunization to red blood cell antigens affects clinical outcomes in liver transplant patients. Liver Transpl 2007; 13: 1654.
41. Pereboom IT, de Boer MT, Haagsman EB, et al. Platelet transfusion during liver transplantation is associated with increased postoperative mortality due to acute lung injury. Anesth Analg 2009; 108: 1083.
42. Boin IF, Leonardi MI, Luzo AC, et al. Intraoperative massive transfusion decreases survival after liver transplantation. Transpant Proc 2008; 40: 789.
43. Chidl CG, Turcotte JG. Surgery and portal hypertension. In: Child CG, ed. The liver and portal hypertension. Philadelphia, Saunders 1964, p 50.
44. Kamath PS, Wiesmer RH, Mallinchoc M, et al. A model to predict survival in patients with end-stage liver disease. Hepatology 2001; 33: 464.
45. Massicotte L, Perrault MA, Denault AY, et al. Effects of phlebotomy and phenylephrine infusion on portal venous pressure and systemic hemodynamics during liver transplantation. Transplantation 2010; 89: 920.
46. Royston D, Bidstrup BP, Taylor KM, et al. Effect of aprotinin on need for blood transfusion after repeat open-heart surgery. Lancet 1987; 2: 1289.